Sara Gastoldi

Science And Technology Park Kilometro Rosso
Bergamo, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Sustained terminal complement inhibition on the endothelium with ravulizumab in patients with atypical Haemolytic Uremic Syndrome.

Sustained terminal complement inhibition on the endothelium with ravulizumab in patients with atypical Haemolytic Uremic Syndrome.

Journal: Nephron

Published: March 05, 2026

Response to the Letter to the Editor Entitled "Defining "Dominance" in Atypical Hemolytic Uremic Syndrome: Distinguishing Amplification From Initiation".

Response to the Letter to the Editor Entitled "Defining "Dominance" in Atypical Hemolytic Uremic Syndrome: Distinguishing Amplification From Initiation".

Journal: Kidney international reports

Published: January 30, 2026

Molecular determinants of STEC-HUS: from complement activation to microvascular thrombosis.

Molecular determinants of STEC-HUS: from complement activation to microvascular thrombosis.

Journal: Frontiers in immunology

Published: November 19, 2025

Complement-Mediated Postpartum Atypical Hemolytic Uremic Syndrome With Collapsing Focal Segmental Glomerulosclerosis Associated With a Novel CFHR5 Copy Number Variant.

Complement-Mediated Postpartum Atypical Hemolytic Uremic Syndrome With Collapsing Focal Segmental Glomerulosclerosis Associated With a Novel CFHR5 Copy Number Variant.

Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation

Published: September 15, 2025

Complement Alternative Pathway Dominance in Atypical Hemolytic Uremic Syndrome Revealed by Endothelial Bioassays.

Complement Alternative Pathway Dominance in Atypical Hemolytic Uremic Syndrome Revealed by Endothelial Bioassays.

Journal: Kidney international reports

Published: August 04, 2025

C3d-targeted complement inhibitors to correct complement dysregulation in aHUS patients.

C3d-targeted complement inhibitors to correct complement dysregulation in aHUS patients.

Journal: Frontiers in immunology

Published: April 30, 2025

Mesenchymal stromal cell secretome reduces lung injury and thrombo-inflammation induced by SARS-CoV-2 spike protein.

Mesenchymal stromal cell secretome reduces lung injury and thrombo-inflammation induced by SARS-CoV-2 spike protein.

Journal: Stem cell research & therapy

Published: February 13, 2025

Case report: Timing of eculizumab treatment in catastrophic antiphospholipid syndrome.

Case report: Timing of eculizumab treatment in catastrophic antiphospholipid syndrome.

Journal: Frontiers in immunology

Published: July 05, 2024

Exuberant Endothelial C5b-9 Formation in Recurrent and De Novo Posttransplant Thrombotic Microangiopathy.

Exuberant Endothelial C5b-9 Formation in Recurrent and De Novo Posttransplant Thrombotic Microangiopathy.

Journal: Kidney international reports

Published: June 11, 2024

Moss-produced human complement factor H with modified glycans has an extended half-life and improved biological activity.

Moss-produced human complement factor H with modified glycans has an extended half-life and improved biological activity.

Journal: Frontiers in immunology

Published: February 06, 2024

An ex vivo test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndrome.

An ex vivo test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndrome.

Journal: Frontiers in immunology

Published: November 30, 2022

Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19.

Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19.

Journal: Frontiers in pharmacology

Published: December 23, 2021

Showing 1-12 of 28

Last Updated: 09/26/2026